Brief: CNS Pharmaceuticals Continues Momentum In Ongoing Potentially Pivotal Global Trial Evaluating Berubicin For The Treatment Of GBM With First Patient Enrolled In Switzerland
09/03/2023 14:09
March 9 (Reuters) - CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS CONTINUES MOMENTUM IN ONGOING
POTENTIALLY
PIVOTAL GLOBAL TRIAL EVALUATING BERUBICIN FOR THE TREATMENT OF
GBM WITH FIRST PATIENT ENROLLED IN SWITZERLAND
Source text for Eikon: ID:nPn5RwkGZa
Further company coverage: CNSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CNS Pharmaceuticals
See all newsCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026